Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.52 |
| ▸ | EGFR | P00533 | 5/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1543410 | 0.77 | PIK3CA (0.62) | PIK3CAEGFRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1543955 | 0.76 | PIK3CA (0.48) | PIK3CAEGFRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1543437 | 0.73 | PIK3CA (0.62) | PIK3CAEGFRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL24576567 | 0.73 | PIK3CA (0.68) | PIK3CAEGFRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL29775072 | 0.73 | PIK3CA (0.68) | PIK3CAEGFRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL730423 | 0.73 | PIK3CA (0.72) | PIK3CAEGFRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL29775103 | 0.71 | PIK3CA (0.66) | PIK3CAEGFRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1544078 | 0.71 | PIK3CA (0.59) | PIK3CAEGFRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL24576570 | 0.71 | PIK3CA (0.66) | PIK3CAEGFRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1543439 | 0.71 | PIK3CA (0.74) | PIK3CAEGFRPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | claimed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | claimed |
| EP-2307400-A2 | INHIBITORS OF PI3 KINASE | Amgen, Inc (US) | 2011-04-13 | — | — | EP | claimed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | claimed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-03-14 | — | — | US | disclosed |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2018-09-13 | — | — | US | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| EP-2307400-A2 | INHIBITORS OF PI3 KINASE | Amgen, Inc (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | PIK3CA 1228/4885EGFR 2297/4885PIK3CD 2515/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | PIK3CA 426/4885EGFR 1810/4885PIK3CD 1353/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | PIK3CA 1228/4885EGFR 2297/4885PIK3CD 2515/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | PIK3CA 426/4885EGFR 1810/4885PIK3CD 1353/4885 |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | PIK3CA 1050/4885EGFR 2109/4885PIK3CD 2262/4885 |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | PIK3CA 1228/4885EGFR 2297/4885PIK3CD 2515/4885 |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, PIK3R1, PIK3R5 | PIK3CA 1/4885EGFR 431/4885PIK3CD 5/4885 |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, CYP11B2 | PIK3CA 1050/4885EGFR 2109/4885PIK3CD 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.